



The Detection of Cardiotoxicity during Cancer Therapy: Biomarkers and/or Imaging
International CardioOncology Society (ICOS) Annual Meeting: Day 1

Friday, September 28, 2012

7:20 am to 8:20 am

Registration & Continental Breakfast

8:15 am to 8:20 am

Welcome: *Giovanni La Canna MD, President of the Italian Society of Cardiovascular Echography*

8:20 am to 8:30 am

Introduction: *Carlo Cipolla, MD and Daniel Lenihan, MD*

8:30 am to 8:40 am

Welcome: *Professor Umberto Veronesi*

8:40 am to 10:20 am (Session 1)

Overview of Cardiotoxicity and the Potential Impact

Moderators: Giuseppe Curigliano, MD, PhD/Joseph Carver, MD

- Integrating the critical role of anthracyclines in cancer therapy and the risk of cardiotoxicity: *Giorgio Minotti, MD (20 minutes)*
- Understanding the biology of cardiac injury is critical to new drug development: *Douglas Sawyer, MD, PhD (20 minutes)*
- Late cardiotoxicity: legend or reality?: *Daniela Cardinale, MD, PhD (20 minutes)*
- Panel Discussion: All speakers (40 minutes)

10:20 am to 10:40 am

Break

10:40 am to 12:20 pm (Session 2)

Anti-angiogenic Therapy in Oncology – is there a Cardiac Concern?

Moderators: Daniel Lenihan, MD / Carlo Tocchetti, MD, PhD

- How useful are anti-angiogenic therapies in cancer treatment?: *Apostolia Tsimberidou, MD, PhD (20 minutes)*
- Is there evidence for a biomarker strategy for cardiac toxicity detection with anti-angiogenic agents?: *Bonnie Ky, MD (20 minutes)*
- Real-World Incidence of Cardiac Toxicity from Tyrosine Kinase Inhibitors/Anti-Angiogenic Therapies – Higher Than You Think: *Ronald Witteles, MD (20 minutes)*
- Panel Discussion: All Speakers (40 minutes)

12:20 pm to 1:20 pm

Lunch

1:20 pm to 2:50 pm (Session 3)

Newer Biomarkers for the Detection of Cardiotoxicity

Moderators: Douglas Sawyer, MD, PhD / Jean-Bernard Durand, MD

- High sensitivity Troponins and Natriuretic Peptides in the early detection of cardiotoxicity: *Maria Teresa Sandri, MD (20 minutes)*
- Mitochondrial mechanisms and markers of cardiotoxicity: *Marco Giorgio, MD, PhD (20 minutes)*
- MAO Inhibitors for protection and treatment of cardiotoxicity: *Fabio Di Lisa, MD (20 minutes)*
- Panel Discussion: All speakers (30 minutes)

2:50 pm to 3:10 pm

Break

3:10 pm to 4:40 pm (Session 4)

Management, Guidelines, and Trial Conduct for Cardiac Issues in Oncology

Moderators: Ron Krone, MD / Vittorio Mattioli, MD

- High dose chemotherapy & stem cell transplantation – How do Oncology & Cardiology Interact with these patients?: *Fabio Ciceri, MD (20 Minutes)*
- Guidelines for the prevention and management of cardiac co-morbidity in Hematology Oncology: *Giovanni Barosi, MD (20 minutes)*
- How can cardiology help in the development and conduct of oncology clinical trials?: *Thomas Suter, MD (20 minutes)*
- Panel Discussion: All speakers (30 minutes)

4:40 pm to 4:50 pm

Break

4:50 pm to 5:50pm (Session 5)

State of the Art of CardiOncology

Moderators: Carol Chen, MD / Giovanni La Canna, MD

- Echocardiography can be a mainstay for ensuring cardiac safety during cancer therapy: *Carlo Tocchetti, MD, PhD (20 minutes)*
- Research opportunities that arise in the overlap between Cardiology & Oncology: *Giuseppe Curigliano, MD, PhD (20 minutes)*
- Panel Discussion: All speakers (20 minutes)

5:50 pm to 6:20 pm

Oral Abstract Session

Moderators: Alessandro Colombo, MD and Carlo Cipolla, MD

International CardiOncology Society (ICOS) Annual Meeting: Day 2

Saturday, September 29, 2012

7:20 am to 8:20 am

Registration & Continental Breakfast

8:20 am to 8:30 am

Introduction: *Daniel Lenihan, MD and Professor Cesare Fiorentini*

8:30 am to 10:10 am (Session 6)

Cardiac Imaging in Oncology Trials

Moderators: Richard Steingart, MD / Maurizio Civelli, MD

- How should the detection of cardiotoxicity be incorporated into phase II and III clinical trials of breast cancer therapy? *Chau Dang, MD Oncology and Jennifer Liu, MD Cardiology (30 minutes)*
- Overview of newer techniques in Echo, including 3-D and contrast vector imaging to detect cardiotoxicity: *Jagat Narula, MD, PhD (20 minutes)*
- Cardiac magnetic resonance: a new diagnostic tool to detect early cardiac toxicity: *Francesco De Cobelli, MD (20 minutes)*
- Panel Discussion: All speakers (30 minutes)

10:10 am to 10:30 am

Break

10:30 am to 12:50 pm (Session 7)

Enhancing Cooperation with Cardiology and Oncology

Moderators: Antonio Pezzano, MD / Boaz Mendzelevski, MD

- How do we integrate biomarkers and imaging in a clinically practical manner to detect cardiotoxicity?: *Daniel Lenihan, MD (20 minutes)*
- What is the optimal strategy to ensure cardiac safety during oncology drug development?: *John Finkle, MD (20 minutes)*
- What should cardiology and oncology's practice goals be to achieve synergy?: *Michael Fisch, MD (20 minutes)*
- What can professional societies do to better integrate care?: *JoAnn Lindenfeld, MD (20 minutes)*
- CardiOncology Patient Care Challenges in Developing Countries: *Goury Shankar Bhattacharyya, MD (20 minutes)*
- Panel Discussion: All Speakers (40 minutes)

12:50 pm to 1:00 pm

Closing Remarks – Plan for CardiOncology 2013

Carlo Cipolla, MD / Daniel Lenihan, MD

Jointly sponsored by:

VANDERBILT UNIVERSITY  School of Medicine

Division of Cardiovascular Medicine and

 IEO
Istituto Europeo di Oncologia

The course programme will be held in English only.

*ECM accreditation (for Italian):
Biologi e Medici Chirurghi specializzati in:
Oncologia Cardiologia
Medicina di Laboratorio
Medicina Interna*